These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8261678)

  • 1. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism.
    Fischer ER; Harris DC
    Clin Nephrol; 1993 Oct; 40(4):216-20. PubMed ID: 8261678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ; Yang CS; Ferng SH; Chen LY
    Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
    Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
    Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
    Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
    Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH; Chiang SS; Huang TP; Shieh SD; Akmal M
    Miner Electrolyte Metab; 1994; 20(3):97-102. PubMed ID: 7816008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol.
    Malberti F; Surian M; Cosci P
    Kidney Int Suppl; 1993 Jun; 41():S125-30. PubMed ID: 8320905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
    Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism.
    Dressler R; Laut J; Lynn RI; Ginsberg N
    Clin Nephrol; 1995 May; 43(5):324-31. PubMed ID: 7634548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravenous calcitriol in the treatment of the refractory secondary hyperparathyroidism of terminal chronic kidney failure].
    Almirall J; Torregrosa V; Arrizabalaga P; Cases A; Oliva J
    Med Clin (Barc); 1994 Mar; 102(9):325-8. PubMed ID: 8164458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
    Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
    Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronotherapy of high-dose 1,25-dihydroxyvitamin D3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study.
    Tsuruoka S; Sugimoto K; Ohmori M; Kawaguchi A; Saito T; Fujimura A
    Clin Pharmacol Ther; 1999 Dec; 66(6):609-16. PubMed ID: 10613617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Low dosage intravenous calcitriol bolus therapy in chronic hemodialysis patients].
    Neyer U; Wöss E; Drexel H
    Acta Med Austriaca; 1994; 21(5):129-32. PubMed ID: 7709710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
    Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
    Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
    Indridason OS; Quarles LD
    Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral calcitriol pulse therapy in treatment of secondary hyperparathyroidism in patients with long term hemodialysis].
    Szołkiewicz M; Zdrojewski Z; Sulima-Gillow A; Rutkowski B
    Przegl Lek; 1996; 53(5):427-30. PubMed ID: 8754407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
    Daisley-Kydd RE; Mason NA
    Pharmacotherapy; 1996; 16(4):619-30. PubMed ID: 8840368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.